Company news

Armata Pharmaceuticals, Inc. news in 2025

Armata Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10: 00am EST

November 18, 2025

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

November 12, 2025

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

November 10, 2025

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

October 22, 2025

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

October 14, 2025

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

September 8, 2025

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 4, 2025

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

August 12, 2025

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 19, 2025

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 14, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

May 1, 2025

2025 Annual Meeting Proxy

April 29, 2025

Annual Report Package for the 2025 Annual Meeting

April 23, 2025

Decks in 2025